Get access

Perspectives of primary care clinicians on teratogenic risk counseling

Authors

  • Eleanor Bimla Schwarz,

    Corresponding author
    1. Center for Research on Health Care, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
    2. Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania
    • 230 McKee Place, Suite 600, Pittsburgh, PA 15213
    Search for more papers by this author
  • Aimee Santucci,

    1. Center for Research on Health Care, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
    Search for more papers by this author
  • Sonya Borrero,

    1. Center for Research on Health Care, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
    2. VA Center for Health Equity Research and Promotion, Pittsburgh, Pennsylvania
    Search for more papers by this author
  • Aletha Y. Akers,

    1. Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania
    Search for more papers by this author
  • Cara Nikolajski,

    1. Center for Research on Health Care, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
    Search for more papers by this author
  • Melanie A. Gold

    1. Center for Research on Health Care, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
    2. Division of Adolescent Medicine, Department of Pediatrics, University of Pittsburgh, Pittsburgh, Pennsylvania
    Search for more papers by this author

  • No conflict of interest disclosed.

Abstract

BACKGROUND: Women of childbearing age are commonly prescribed medications by primary care providers (PCPs) that may cause birth defects if used during pregnancy. METHODS: To identify what PCPs perceive as barriers to and potential facilitators of providing counseling to women of childbearing age when teratogenic medications are prescribed, we conducted eight focus groups with 48 PCPs recruited from four clinical settings in Pittsburgh, Pennsylvania. We explored PCPs' experiences counseling women about teratogenic medications. Each focus group was audio-recorded, transcribed, and coded using a grounded theory approach by three independent coders. RESULTS: PCPs feel responsible for counseling women when they prescribe medications that may cause birth defects, but note difficulties identifying clinically relevant sources of information on teratogenicity. Other barriers to providing counseling include limited visit times and lack of reimbursement for preconception or teratogenic risk counseling. PCPs find it challenging to identify patients who may become pregnant and who therefore need contraceptive and/or teratogenic risk counseling. PCPs expressed a desire for online resources that could be used when explaining medication risks to patients. PCPs feel that the development of patient information materials, electronic decision support tools, clinical care systems that routinely assess patients' pregnancy risk, and changes in the reimbursement structure may facilitate counseling patients about teratogenic risks. CONCLUSIONS: PCPs perceive themselves as playing an important role in providing their patients information on risk of medication-induced birth defects. To ensure safe prescription of teratogenic medications, PCPs suggest interventions at both the clinic and healthcare system levels. Birth Defects Research (Part A), 2009. © 2009 Wiley-Liss, Inc.

Ancillary